Stocks · News reference
Caribou Biosciences reported its financial results for the third quarter of 2026, highlighting a net loss of $26.6 million and ongoing strategic restructuring efforts.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Caribou Biosciences announced that clinical abstracts for its vispa-cel and CB-011 programs have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
HC Wainwright & Co. analyst Robert Burns downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Neutral.